- Home
- WSHP vs MNOV Comparison
WSHP vs MNOV Comparison
Compare WSHP & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WSHP | MNOV |
|---|---|---|
| Founded | 2021 | 2000 |
| Country | British Virgin Islands | United States |
| Employees | 20 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.8M | 67.9M |
| IPO Year | N/A | 2004 |
Fundamental Metrics
Financial Performance| Metric | WSHP | MNOV |
|---|---|---|
| Price | $5.35 | $1.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | ★ 64.7K | 37.0K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,360,807.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $180.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 194.15 |
| 52 Week Low | $4.33 | $1.17 |
| 52 Week High | $250.00 | $1.96 |
Technical Indicators
Market Signals| Indicator | WSHP | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 42.32 | 39.58 |
| Support Level | N/A | $1.24 |
| Resistance Level | $7.50 | $1.46 |
| Average True Range (ATR) | 0.54 | 0.04 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 26.71 | 6.67 |
Price Performance
Historical ComparisonAbout WSHP WeShop Holdings Limited Class A Ordinary Shares
WeShop Holdings Ltd is a community owned social commerce platform offering shoppers shares in the company every time customers make a purchase, recommend a product or refer a new member. WeShop earns revenues from advertising on their platform and commissions on the sales through the platform.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.